» Articles » PMID: 35314468

Impact of the COVID-19 Pandemic on Gastrointestinal Infection Trends in England, February-July 2020

Overview
Journal BMJ Open
Specialty General Medicine
Date 2022 Mar 22
PMID 35314468
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To establish the impact of the first 6 months of the COVID-19 outbreak response on gastrointestinal (GI) infection trends in England.

Design: Retrospective ecological study using routinely collected national and regional surveillance data from seven UK Health Security Agency coordinated laboratory, outbreak and syndromic surveillance systems using key dates of UK governmental policy change to assign phases for comparison between 2020 and historic data.

Results: Decreases in GI illness activity were observed across all surveillance indicators as COVID-19 cases began to peak. Compared with the 5-year average (2015-2019), during the first 6 months of the COVID-19 response, there was a 52% decrease in GI outbreaks reported (1544 vs 3208 (95% CI 2938 to 3478)) and a 34% decrease in laboratory confirmed cases (27 859 vs 42 495 (95% CI 40 068 to 44 922)). GI indicators began to rise during the first lockdown and lockdown easing, although all remained substantially lower than historic figures. Reductions in laboratory confirmed cases were observed across all age groups and both sexes, with geographical heterogeneity observed in diagnosis trends. Health seeking behaviour changed substantially, with attendances decreasing prior to lockdown across all indicators.

Conclusions: There has been a marked change in trends of GI infections in the context of the COVID-19 pandemic. The drivers of this change are likely to be multifactorial; while changes in health seeking behaviour, pressure on diagnostic services and surveillance system ascertainment have undoubtably played a role, there has likely been a true decrease in the incidence for some pathogens resulting from the control measures and restrictions implemented. This suggests that if some of these changes in behaviour such as improved hand hygiene were maintained, then we could potentially see sustained reductions in the burden of GI illness.

Citing Articles

Epidemiology of Shiga toxin-producing other than serotype O157:H7 in England, 2016-2023.

King G, Jenkins C, Hayden I, Rodwell E, Quinn O, Godbole G J Med Microbiol. 2025; 74(1.

PMID: 39791999 PMC: 11721027. DOI: 10.1099/jmm.0.001947.


Impact of non-pharmaceutical interventions during the COVID-19 pandemic on pathogens transmitted via food in the Netherlands.

Pijnacker R, Mughini-Gras L, Verhoef L, van den Beld M, Franz E, Friesema I Epidemiol Infect. 2024; 152:e130.

PMID: 39434376 PMC: 11502420. DOI: 10.1017/S0950268824000815.


Analyzing the dynamics of complicated and uncomplicated appendicitis during the COVID-19 pandemic in Seoul, Korea: a multifaceted time series approach.

Baek K, Park C Epidemiol Health. 2024; 46:e2024081.

PMID: 39363604 PMC: 11832239. DOI: 10.4178/epih.e2024081.


Children hospitalised with gastroenteritis before and during the COVID-19 pandemic.

Saidian H, Daugberg R, Jensen L, Schoos A, Rytter M Acta Paediatr. 2024; 114(1):148-155.

PMID: 39235259 PMC: 11627442. DOI: 10.1111/apa.17418.


Understanding the impact funding cuts on Environmental and regulatory services and gastrointestinal infections: a longitudinal ecological study.

Murrell L, Clough H, Gibb R, Zhang X, Green M, Chattaway M NIHR Open Res. 2024; 3:41.

PMID: 39139278 PMC: 11320035. DOI: 10.3310/nihropenres.13426.2.


References
1.
Cowling B, Ali S, Ng T, Tsang T, Li J, Fong M . Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet Public Health. 2020; 5(5):e279-e288. PMC: 7164922. DOI: 10.1016/S2468-2667(20)30090-6. View

2.
Tam C, Rodrigues L, Viviani L, Dodds J, Evans M, Hunter P . Longitudinal study of infectious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general practice. Gut. 2011; 61(1):69-77. PMC: 3230829. DOI: 10.1136/gut.2011.238386. View

3.
Melidou A, Pereyaslov D, Hungnes O, Prosenc K, Alm E, Adlhoch C . Virological surveillance of influenza viruses in the WHO European Region in 2019/20 - impact of the COVID-19 pandemic. Euro Surveill. 2020; 25(46). PMC: 7678039. DOI: 10.2807/1560-7917.ES.2020.25.46.2001822. View

4.
Elliot A, Harcourt S, Hughes H, Loveridge P, Morbey R, Smith S . The COVID-19 pandemic: a new challenge for syndromic surveillance. Epidemiol Infect. 2020; 148:e122. PMC: 7338397. DOI: 10.1017/S0950268820001314. View

5.
Moroni F, Gramegna M, Ajello S, Beneduce A, Baldetti L, Vilca L . Collateral Damage: Medical Care Avoidance Behavior Among Patients With Myocardial Infarction During the COVID-19 Pandemic. JACC Case Rep. 2020; 2(10):1620-1624. PMC: 7252183. DOI: 10.1016/j.jaccas.2020.04.010. View